Nordholz Germany

https://www.frontiersin.org › journals › immunology › articles › full
Based on real world data this study aimed to investigate the clinical outcomes safety profile and the quality of life

https://link.springer.com › article
Introduction Myasthenia gravis MG is a chronic autoimmune neuromuscular disorder needing long term

https://www.frontiersin.org › journals › immunology › articles › full
Eculizumab demonstrated clinical improvement in this series and the treatment was well tolerated This case series

https://www.thelancet.com › journals › laneur › article › fulltext
Results from a phase 2 study suggested that eculizumab a terminal complement inhibitor produced clinically

https://pubmed.ncbi.nlm.nih.gov
Abstract Introduction Eculizumab is effective and well tolerated in patients with antiacetylcholine receptor antibody positive refractory

https://dukespace.lib.duke.edu › server › api › core › bitstreams
Myasthenia gravis exacerbation rate was reduced by 75 from the year before REGAIN P 0 0001 Improvements with eculi

https://link.springer.com › article
Introduction Eculizumab a complement active antibody and efgartigimod an Fc fragment that blocks neonatal Fc

https://www.accessdata.fda.gov › drugsatfda_docs › label
Eculizumab aagh is indicated for the treatment of generalized myasthenia gravis gMG in adult patients who are anti acetylcholine

https://journals.plos.org › plosone › article › file
The number of meningococcal infections and associated deaths among eculizumab and ravulizumab treated